Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2015
Reporting Period: Third Quarter 2015
This filing announces the results of operations for the third quarter of 2015. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release) and are not included in the body of this 8-K document.
The company utilizes non-GAAP financial measures to assess performance, specifically:
- Net earnings excluding specified items.
- Adjustments for unusual or unpredictable factors, including cost reduction initiatives and transaction-related costs.
- Exclusions for tax expenses related to a one-time repatriation of ex-U.S. earnings.
- Exclusions for gains on the sale of a portion of Abbott's position in Mylan stock.
- Exclusions for decreases in the fair value of contingent consideration related to business acquisitions.
- Exclusion of intangible amortization expense.
Material Changes and Unusual Items
The filing identifies several specific items that management considers unusual or unpredictable, which are adjusted for in their non-GAAP reporting:
- Cost reduction initiatives.
- Transaction-related costs.
- Tax expense associated with a one-time repatriation of ex-U.S. earnings.
- Gain on the sale of a portion of Abbott's position in Mylan stock.
- Decrease in the fair value of contingent consideration related to a business acquisition.
The filing does not provide a quantitative comparison of these items versus the prior comparable period.
Guidance, Outlook, and Management Commentary
Management states that the presentation of non-GAAP financial measures provides useful information for evaluating ongoing business performance and is used internally to monitor business performance. However, Abbott cautions investors to consider these non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.
The filing text does not contain specific forward-looking guidance, updated outlook figures, or detailed risk contingencies beyond the standard caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2015 revenue, net earnings, and cash flow figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the impact of the Mylan stock sale and repatriation tax expense.
- Assess the magnitude of intangible amortization expense excluded from non-GAAP results.
- Confirm the details of the "cost reduction initiatives" and "transaction-related costs" impacting the quarter.